ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2395

Analysis of histopathological changes in the placenta of patients with systemic lupus erythematosus

Bartira Melo1, Elizabeth Avvad2, Marcela lacerda2, Nilson jesus2, Evandro Klumb2 and Guilherme Ramires de Jesus3, 1UERJ- Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 2UERJ - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 3Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Rio de Janeiro, Brazil

Meeting: ACR Convergence 2025

Keywords: pregnancy, Systemic lupus erythematosus (SLE), Women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic lupus erythematosus (SLE) is more frequent in women of reproductive age and pregnancy in these patients is considered as high risk. The inflammatory environment, with exacerbated activation of the complement system, formation, and tissue deposition of immune complexes promote placental histopathological changes that predispose to pregnancy complications. The objective of this study was to describe histopathological findings in the placentas of pregnant women with SLE and correlate them with adverse outcomes.

Methods: Patients with SLE (ACR criteria 1997) and singleton pregnancies, who received prenatal care at a tertiary hospital and delivered at the same institution, were included. They were divided in four groups: Group 1 – Preeclampsia (PE)/intrauterine growth restriction (IUGR); Group 2 – Active SLE (SLEPDAI > 4); Group 3 – Systemic infection during pregnancy; Group 4 – patients without PE/IUGR, active SLE or infection. Histopathological analysis of the placentas was performed according to Amsterdan Placental Workshop Group Consensus Statement.

Results: Ninety-seven patients were included and histopathological study of the placenta was performed in all cases by blinded pathologists for pregnancy outcome. Adverse outcomes were observed in 49 (50.5%) pregnancies. PE/IUGR was the most frequent, being found in 28 (28.8%) patients. Disease activity during pregnancy was diagnosed in 23 (23.7%) cases and an episode of systemic infection was identified in 13 (13.4%) pregnant women. Fifteen women were analyzed in more than one group due to multiple events (e.g., PE/CIUR and SLE activity). Considering all patients, maternal vascular hypoperfusion abnormalities (MVHA) were the most frequent histopathological findings: 19 (19.6%) had moderate to severe major MVHA; 59 (60.8%) had mild major MVHA; and 83 (85.6%) presented minor MVHA. Patients in Group 2 (PE/IUGR) had more frequently moderate to severe major MVHA compared to the other groups (32.1% x 14.5%, p=0.047), while patients in Group 4 (no studied outcomes) had significantly less acute fetal vascular hypoperfusion abnormalities (FVHA) (14.3% x 33.3%, p=0.027). In both Groups 2 (active SLE) and 3 (systemic infection), the most common finding was minor MVHA (82.6% and 84.6%, respectively), but there was no statistical difference compared to the other groups. Significant risk predictors for the outcome PE/IUGR were absence of acute (FVHA) (p=0.025), presence of hematogenous infection (p=0.005), presence of small for gestational age (SGA) newborn (p < 0.0001), need for neonatal intensive care unit (p=0.002), lower gestational age at delivery (p=0.0003) and lower birth weight (p < 0.0001). No variable was a significant predictor for the outcome disease activity and systemic infection. Based on multivariate analysis, it was observed that SGA newborn (p < 0.0001) and hematogenous infection (p=0.015) were significant independent variables to predict the PE/IUGR outcome.

Conclusion: This study demonstrates that MVHA are commonly found in placentas of patients with SLE. Moderate to severe MVHA are more frequent in patients who develop PE/IUGR, which may be linked to the pathophysiology of these obstetric adverse outcomes.


Disclosures: B. Melo: None; E. Avvad: None; M. lacerda: None; N. jesus: None; E. Klumb: None; G. Ramires de Jesus: None.

To cite this abstract in AMA style:

Melo B, Avvad E, lacerda M, jesus N, Klumb E, Ramires de Jesus G. Analysis of histopathological changes in the placenta of patients with systemic lupus erythematosus [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/analysis-of-histopathological-changes-in-the-placenta-of-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-histopathological-changes-in-the-placenta-of-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology